Insider TradingJul 23, 2026, 12:02 PM
OKYO Pharma Director John Brancaccio Buys 5,000 Shares at $1.48
AI Summary
OKYO Pharma announced that its Non-Executive Director, John Brancaccio, purchased 5,000 of the company's ordinary shares on NASDAQ at $1.48 per share. This transaction brings his total holding to 35,201 shares, signaling confidence in the company. OKYO Pharma, a clinical-stage biopharmaceutical company, is preparing to initiate a global Phase 3 pivotal clinical trial for urcosimod in the second half of this year, targeting neuropathic corneal pain.
Key Highlights
- OKYO Pharma Non-Executive Director John Brancaccio purchased 5,000 ordinary shares.
- Shares were bought on NASDAQ at $1.48 per share.
- This purchase increases his total holding to 35,201 shares.
- OKYO Pharma is a clinical-stage biopharmaceutical company.
- The company plans to initiate a global Phase 3 clinical trial for urcosimod in H2 2026.
- The Phase 3 trial will enroll approximately 111 patients for neuropathic corneal pain (NCP).
Price Impact
More from OKYO